Vanda Pharmaceuticals Inc (VNDA.OQ)

VNDA.OQ on NASDAQ Stock Exchange Global Market

10.09USD
4:00pm EDT
Change (% chg)

$-0.01 (-0.10%)
Prev Close
$10.10
Open
$10.05
Day's High
$10.19
Day's Low
$9.99
Volume
233,757
Avg. Vol
193,653
52-wk High
$16.49
52-wk Low
$8.34

VNDA.OQ

Chart for VNDA.OQ

About

Vanda Pharmaceuticals Inc. is a biopharmaceutical company engaged in the development and commercialization of products for the treatment of central nervous system disorders. The Company’s product portfolio includes: HETLIOZ (tasimelteon), a product for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24); Fanapt (iloperidon... (more)

Overall

Beta: 1.98
Market Cap(Mil.): $422.16
Shares Outstanding(Mil.): 41.80
Dividend: --
Yield (%): --

Financials

  VNDA.OQ Industry Sector
P/E (TTM): 11.91 295.26 38.09
EPS (TTM): 0.85 -- --
ROI: 28.36 -5.72 15.45
ROE: 42.08 -6.68 16.49
Search Stocks

Vanda's eczema drug fails mid-stage study, shares fall

- Vanda Pharmaceuticals Inc said its experimental atopic dermatitis drug failed a mid-stage study to treat chronic itching.

04 Mar 2015

UPDATE 1-Vanda's eczema drug fails mid-stage study, shares fall

March 4 - Vanda Pharmaceuticals Inc said its experimental atopic dermatitis drug failed a mid-stage study to treat chronic itching.

04 Mar 2015

Vanda's eczema drug fails mid-stage study

March 4 - Vanda Pharmaceuticals Inc said its experimental atopic dermatitis drug failed a mid-stage study to treat chronic itching, sending its shares down 8.7 percent in after-hours trading.

04 Mar 2015

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Jefferson Research
$20.00
Provider: Sadif Analytics Prime
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks